fbpx

Biogen Surges on Promising Alzheimer’s Drug Assessment

Biogen Surges on Promising Alzheimer’s Drug Assessment

Biogen Inc. received a big boost on Wednesday after U.S. Food and Drug Administration regulators appeared to give a positive assessment of the company

Retailers Cut Back on Choices; ‘We Don’t Need Three Types of Red’
Black Friday Deals Are More Tame as Coronavirus Alters Sales Strategies
What Stays and What Goes in a Post-Covid-19 World

Biogen Inc. received a big boost on Wednesday after U.S. Food and Drug Administration regulators appeared to give a positive assessment of the company’s experimental Alzheimer’s disease drug, sending shares up 44%.

The biotech giant is at a crossroads as it seeks regulatory approval for its potential blockbuster Alzheimer’s drug aducanumab, while facing down generic competition to its biggest-selling treatment.

Soon…

This post first appeared on wsj.com

Do You Enjoy This Article?
Sign up for our newsletter and receive FREE access to download SuccessDigest Digital Weekly Edition for attainment of your financial freedom in the new digital economy!

Invalid email address
We promise not to spam you. You can unsubscribe at any time.

COMMENTS

WORDPRESS: 0
DISQUS: 0
%d bloggers like this: